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Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL
patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP
era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an
emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab
has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of
rituximab is largely restricted to CD44H-positive cases in this cohort.
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Although incorporation of rituximab into CHOP (R-
CHOP) has dramatically improved the outcome of DLBCL
[1-5], approximately 40% of patients still succumb to the
disease [6]. One of the prognostic markers studied in the
CHOP era is CD44, a transmembrane glycoprotein with
many alternative splicing isoforms [7]. Variations in its
extracellular domain lead to isoform-specific activities
of CD44 in cell adhesion, lymphocyte homing, and cell
signaling [7]. In general, CD44 plays a positive role in cell
survival and invasiveness, and it is implicated in cancer
stem cell maintenance in certain solid tumors [8]. The
objective of the current study is to compare the prognostic
significance of CD44 isoforms in the CHOP and R-CHOP
treatment groups.
This study enrolled 117 de novo DLBCL patients among
whom 53 were treated with CHOP and 64 were treated with
R-CHOP (Additional file 1; Additional file 2: Table S1). As
expected, the incorporation of rituximab markedly im-
proved the overall survival (OS) and event-free survival
(EFS) rates (not shown). We used immunohistochemis-
try (IHC) to examine the expression of CD44H (the
standard isoform) and CD44v6 (isoforms containing the* Correspondence: ruth1626@hotmail.com; hilda.ye@einstein.yu.edu
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unless otherwise stated.variant exon 6) in diagnostic specimens (Additional file 3:
Figure S1). Expression of CD44H and CD44v6 was de-
tected in 65.0% and 34.2% of patients, respectively, with
strong correlation to each other (Spearman’s correlation,
r = 0.423, p < 0.001). The baseline clinical features were
not significantly different between the CD44H+ and
CD44H- patients. The CD44v6+ and CD44v6- cases were
also very comparable (Additional file 2: Table S2).
In the entire cohort of 117 patients, CD44H positivity
strongly correlated with poor OS (p = 0.002, Figure 1A)
and EFS (p = 0.011, Figure 1B) outcomes. Specifically, the
5-year OS rates in the CD44H+ and CD44H- subgroups
were 82% and 41%, respectively. CD44v6 positivity also
correlated with poor prognosis, although the trend was
only marginally significant (OS: p = 0.050; EFS: P = 0.058,
Figure 1C and D). Nevertheless, because CD44v6 showed
an IPI-independent survival impact in multi-variable
analysis (Additional file 2: Table S3), the relatively weak
survival association based on the Kaplan-Meier estimates
likely reflects the low frequency of CD44v6 expression and
hence a greater sample size requirement. CD44v6 did not
show any prognostic value when the cohort was divided
into treatment subgroups (not shown). The negative prog-
nostic value for CD44H detected among all patients could
also be observed in the CHOP subgroup (OS: p = 0.021;
EFS: P = 0.044, Figure 1E and F), but not the R-CHOP
subgroup (OS: p = 0.095; EFS: P = 0.211, Figure 1G and H).
Because the OS response was very similar among all R-
CHOP-treated cases and CHOP-treated CD44H- patients,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Overall survival (OS) and event-free survival (EFS) according to CD44H and CD44v6 expression status and type of therapy.
The Kaplan-Meier method was used to estimate the OS and EFS distributions with the log-rank test performed to compare the survival curves. OS
(A and C) and EFS (B and D) of all patients were analyzed based on their CD44H (A and B) and CD44v6 (C and D) status. OS (E and G) and EFS
(F and H) according to CD44H expression status were also analyzed in the CHOP (E and F) and R-CHOP (G and H) treatment groups separately.
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CHOP among CD44H-positive patients may have been
specifically ameliorated by rituximab. To test this notion,
the rituximab-associated survival benefit was examined in
patient subgroups of different CD44 expression status. ForFigure 2 Rituximab-associated survival benefits based on CD44H and
estimate the OS and EFS distributions with the log-rank test performed to com
or CD44H- (C and D), survival outcomes after CHOP and R-CHOP treatments
R-CHOP comparison was also made for OS (E and G) and EFS (F and H) amoCD44H, although rituximab substantially improved the
outcome for CD44H+ patients (OS: p < 0.001; EFS: P =
0.001, Figure 2A and B), the impact of this agent was insig-
nificant for the CD44H- cases (OS: p = 0.093; EFS: P =
0.183, Figure 2C and D). Interestingly, this phenomenonCD44v6 expression status. The Kaplan-Meier method was used to
pare the survival curves. For cases that were either CD44H+ (A and B)
were compared for OS (A and C) and EFS (B and D). CHOP versus
ng the CD44V6+ (E and F) and CD44v6- (G and H) subgroups.
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associated survival benefit was significant irrespective of the
CD44v6 status (Figure 2E to H).
Possibly due to the use of different antibodies and
different IHC staining/scoring methods, there have
been some controversial observations on the prognos-
tic importance of CD44 in CHOP-treated DLBCL
patients. In agreement with the majority of published
studies [9-11], we have observed a negative survival
impact of CD44H and CD44v6 expression in our entire
study cohort (Figure 1 and Additional file 2: Table S3) as
well as the CHOP treatment group (Figure 1E and F), al-
though there were differences between these two markers.
As the first study aimed to examine CD44 isoform
expression in the R-CHOP era, our data suggest that
rituximab has decreased the prognostic significance of
CD44H, while the impact of rituximab on CD44v6
awaits future studies of larger cohorts. We also ob-
served that the rituximab-associated survival benefit
was profound among CD44H-positive cases but fairly
limited among the CD44H-negative subgroup.Additional files
Additional file 1: Information on Patients and Methods.
Additional file 2: Table S1. Clinical features and CD44 variant
expression in the CHOP and RCHOP groups. Table S2. Patient
characteristics according to CD44H and CD44v6 expression status.
Table S3. Prognostic factors and multivariable survival analysis.
Additional file 3: Figure S1. Representative immunohistochemical
staining of DLBCL samples for CD44H and CD44v6 expression. (A, C),
negative control stain using isotype-matched Abs. (B) CD44H staining in
apositive case. (D) CD44v6 staining in a positive case.Competing interests
The authors declare no conflicts of interest.Authors’ contributions
FR and BHY designed the study and analyzed and interpreted the data. WXL
and XM collected and analyzed data. WYQ and HF collected data. ZT and LXZ
provided study material and helped with the IHC staining. BHY, WXL and FR
wrote the manuscript. All authors read and approved the final manuscript.Acknowledgements
This work was supported by the National Natural Science Foundation of
China (Grant No. 81028013), the Science and Technology Project of
Guangdong Province of China (Grant No. 2010B050700020), the Science
and Technology Project of Guangzhou City (Grant No. 12C22121553), and
a pilot grant from CFAR, the Center for AIDS Research at the Albert
Einstein College of Medicine.
Author details
1Department of Hematology, Nanfang Hospital, Southern Medical University,
Guangzhou, China. 2Department of Pathology, Nanfang Hospital, Southern
Medical University, Guangzhou, China. 3Department of Cell Biology, Albert
Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.
Received: 21 February 2014 Accepted: 24 March 2014
Published: 16 April 2014References
1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P,
Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C:
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002,
346(4):235–242.
2. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA,
Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ: Rituximab-
CHOP versus CHOP alone or with maintenance rituximab in older
patients with diffuse large B-cell lymphoma. J Clin Oncol: Official J Am
Soc Clin Oncol 2006, 24(19):3121–3127.
3. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E,
Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho
A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B,
Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M;
German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): Six
versus eight cycles of bi-weekly CHOP-14 with or without rituximab in
elderly patients with aggressive CD20+ B-cell lymphomas: a randomised
controlled trial (RICOVER-60). Lancet Oncol 2008, 9(2):105–116.
4. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K,
Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger
U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied
N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial
Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemo-
therapy alone in young patients with good-prognosis diffuse large-B-cell
lymphoma: a randomised controlled trial by the MabThera International
Trial (MInT) Group. Lancet Oncol 2006, 7(5):379–391.
5. Cang S, Mukhi N, Wang K, Liu D: Novel CD20 monoclonal antibodies for
lymphoma therapy. J Hematol Oncol 2012, 5:64.
6. Sehn LH: Paramount prognostic factors that guide therapeutic strategies
in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ
Program 2012, 2012:402–409.
7. Ponta H, Sherman L, Herrlich PA: CD44: from adhesion molecules to
signalling regulators. Nat Rev Mol Cell Biol 2003, 4(1):33–45.
8. Guo W, Frenette PS: Alternative CD44 splicing in intestinal stem cells and
tumorigenesis. Oncogene 2013.
9. Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST:
Adhesion molecules in the prognosis of diffuse large-cell lymphoma:
expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18),
and ICAM-1 (CD54). Leukemia 1990, 4(8):595–599.
10. Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T: Prognostic significance of
CD44v6 in diffuse large B-cell lymphoma. Mod Pathol 1999, 12(5):546–552.
11. Drillenburg P, Wielenga VJ, Kramer MH, van Krieken JH, Kluin-Nelemans HC,
Hermans J, Heisterkamp S, Noordijk EM, Kluin PM, Pals ST: CD44 expression
predicts disease outcome in localized large B cell lymphoma.
Leukemia 1999, 13(9):1448–1455.
doi:10.1186/1756-8722-7-34
Cite this article as: Wei et al.: The addition of rituximab to CHOP
therapy alters the prognostic significance of CD44 expression. Journal of
Hematology & Oncology 2014 7:34.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
